Integrated Pulmonary Index in Gastroscopic Procedures

NCT ID: NCT05829486

Last Updated: 2023-08-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-02-06

Study Completion Date

2023-11-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Various complications are the leading cause of morbidity in sedation practices in endoscopic procedures, and guidelines recommend continuous monitoring of circulation, respiratory function, and ventilation. Integrated Pulmonary Index (IPI), one of the methods that can be used in this monitoring, gives a single numerical value obtained by continuous and simultaneous joint mathematical analysis of Oxygen saturation, End-tidal carbon dioxide concentration, respiratory rate, and heart rate values and is a good monitorization in these interventions. and provides tracking. In this study, the aim is to determine the role of IPI in the diagnosis and follow-up of respiratory complications in patients who were sedated during gastroscopy procedures.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

IPI EtCO2 is a monitoring method consisting of respiratory rate, SPO2 and heart rate parameters. While EtCO2 is measured with nasal capnography, SPO2, heart rate, respiratory rate are measured with finger probe and it will show instant measurement of respiratory status. IPI takes values between 1-10. An IPI value of 8 and above will indicate normal values, a value between 5-7 will indicate that the respiratory status of the patient should be carefully examined and intervened if necessary, values of 4 and below will definitely indicate that the patient's respiratory status should be intervened.

Blood pressure measurement will be made with a sphingmomanometer noninvasively at certain time intervals with the help of a cuff that will be placed on the patient's arm area.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Endoscopy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ketaprop

At the beginning of anesthesia, 0.25 mg/kg ketamine and 0.75 mg/kg propofol will be administered.

gastroscopy

Intervention Type PROCEDURE

anaesthetic management of ambulatory endoscopic procedures

remiprop

At the beginning of anesthesia, 1 mcg/kg of remifentanil and 0.75 mg/kg propofol will be administered.

gastroscopy

Intervention Type PROCEDURE

anaesthetic management of ambulatory endoscopic procedures

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

gastroscopy

anaesthetic management of ambulatory endoscopic procedures

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ASA 1-2-3 risk scored patients,
* patients over the age of 18 who will undergo endoscopic intervention

Exclusion Criteria

* Patients who need mechanical ventilator support,
* patients who need emergency endoscopic intervention,
* patients with a history of substance abuse,
* patients with a history of allergy to the drugs to be used,
* pregnant women will be excluded from the study.
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Gaziosmanpasa Research and Education Hospital

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Zuhal Çavuş

Medical doctor, principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

zuhal çavuş, MD

Role: PRINCIPAL_INVESTIGATOR

gaziosmanpasa TREH

döndü genç moralar, MD

Role: STUDY_DIRECTOR

gaziosmanpasa TREH

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Gaziosmanpaşa TREH

Istanbul, Gaziosmanpaşa, Turkey (Türkiye)

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

sibel bektas, MD

Role: CONTACT

02129453030

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

sibel bektaş, prof.MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

147/22

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effects of WN and WF During Gastroscopy
NCT06333431 NOT_YET_RECRUITING NA